SCHEMBL20135343

SCHEMBL20135343

Cc1ccc(C2(C)NC(=O)NC2=O)cc1Br

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.52
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
TNKS O95271 1/20 0.39
TNF P01375 1/20 0.35
ADAM17 P78536 1/20 0.34
MMP2 P08253 2/20 0.34
MMP9 P14780 2/20 0.34
PTGER3 P43115 1/20 0.34
BCHE P06276 1/20 0.33
CES1 P23141 1/20 0.33
CACNA1F O60840 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33
HTR2A P28223 1/20 0.33
HRH1 P35367 1/20 0.33
SCN1A P35498 1/20 0.33
SCN4A P35499 1/20 0.33
BLM P54132 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL542616 0.83 LMNA (0.51) LMNAMEN1KMT2ATNKSADAM17
SCHEMBL20135551 0.81 LMNA (0.52) LMNAMEN1KMT2ATNKSTNF
SCHEMBL20134959 0.81 LMNA (0.52) LMNAMEN1KMT2ATNKSTNF
SCHEMBL20134957 0.81 LMNA (0.52) LMNAMEN1KMT2ATNKSTNF
SCHEMBL29688463 0.81 LMNA (0.52) LMNAMEN1KMT2ATNKSTNF
SCHEMBL20135103 0.79 LMNA (0.48) LMNAMEN1KMT2ATNKSADAM17
SCHEMBL1172864 0.79 LMNA (0.50) LMNAMEN1KMT2ATNKSMMP2
SCHEMBL1172865 0.79 LMNA (0.50) LMNAMEN1KMT2ATNKSMMP2
SCHEMBL204119 0.78 LMNA (0.51) LMNAMEN1KMT2ATNKSADAM17
SCHEMBL4385865 0.78 LMNA (0.51) LMNAMEN1KMT2ATNKSADAM17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 LMNA 4264/4885MEN1 3735/4885KMT2A 2568/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 LMNA 4113/4885MEN1 2913/4885KMT2A 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.